Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 8/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.47 |
| ▸ | CDK2 | P24941 | 4/20 | 0.47 |
| ▸ | AURKA | O14965 | 3/20 | 0.47 |
| ▸ | PLK1 | P53350 | 3/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 6/20 | 0.44 |
| ▸ | TTK | P33981 | 3/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.41 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7125143 | 0.86 | IKBKB (0.49) | IGF1RCCNA2CDK2KDRCDK1 | |
| SCHEMBL7239285 | 0.78 | KDR (0.63) | IGF1RPLK1KDR | |
| SCHEMBL7127974 | 0.78 | IGF1R (0.52) | IGF1RCCNA2CDK2AURKAPLK1 | |
| SCHEMBL7511692 | 0.78 | IGF1R (0.48) | IGF1RCCNA2CDK2AURKAPLK1 | |
| Hydrochloric Acid SCHEMBL7518134 | 0.77 | KDR (0.62) | IGF1RPLK1KDR | |
| Hydrochloric Acid SCHEMBL7517919 | 0.77 | IGF1R (0.47) | IGF1RCCNA2CDK2AURKAPLK1 | |
| SCHEMBL7510711 | 0.76 | KDR (0.55) | IGF1RCCNA2CDK2AURKAPLK1 | |
| SCHEMBL7124250 | 0.75 | ABL1 (0.48) | IGF1RCCNA2CDK2AURKAPLK1 | |
| Hydrochloric Acid SCHEMBL7512667 | 0.75 | KDR (0.54) | IGF1RCCNA2CDK2AURKAPLK1 | |
| SCHEMBL7510604 | 0.75 | KDR (0.52) | IGF1RCCNA2CDK2AURKAPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| WO-2001087845-A2 | N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | IGF1R 2519/4885CCNA2 105/4885CDK2 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.